23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition contribution from Family Beginnings, reinforcing INVO’s two primary growth avenues SARASOTA, Fla., June 22, 2026 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the first quarter ended March 31, 2026. Q1 2026 Financial Highlights (all metrics compared to Q1 2025 unless otherwise noted)Revenue was $2,015,225, an increase of 23% compared to $1,637,185. Consolidated clinic revenue increased...

Circle8 Acquisition Establishes Global Workforce Solutions Platform Across North America and Europe ENGLEWOOD CLIFFS, N.J., June 22, 2026 (GLOBE NEWSWIRE) — Atlantic International Corp. (Nasdaq: ATLN) today reported financial results for the first quarter ended March 31, 2026, and filed its Quarterly Report on Form 10-Q with the Securities and Exchange Commission. The quarter reflects the first contribution of Circle8 Group following the completion of the acquisition on January 23, 2026. The transaction meaningfully expanded Atlantic’s geographic reach and operating scale, establishing the Company as a transatlantic workforce solutions platform. The quarter also reflects the initial integration of Circle8 and includes acquisition-related accounting and financing impacts associated with the transaction. First Quarter 2026...

HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) — Fervo Energy Company (“Fervo” or the “Company”) (NASDAQ: FRVO), a leading technology-enabled independent power producer of Enhanced Geothermal Systems (EGS), today reported financial and operational results for the first quarter ended March 31, 2026.“This is the geothermal decade, and Fervo is leading the charge,” said Tim Latimer, CEO and Co-founder of Fervo. “2026 is already off to a transformative start. We completed the largest primary energy and power IPO in recent memory, raising $2.2 billion to accelerate our multi-gigawatt development pipeline and near-term execution at Cape Station, the world’s largest enhanced geothermal project, which is on track for first power in Q4 2026. With 658 megawatts of contracted power purchase agreements and a 3-gigawatt geothermal framework agreement...

Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) —  SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced its financial results for the full year ended December 31, 2025. Management Commentary “2025 was a highly transformative and foundational year for SL Science as we aggressively advanced our core cell therapy pipeline and executed our long-term strategic shift toward next-generation immunotherapies. Throughout the past year, we strategically prioritized our resources on high-value clinical research and development, committing over $2.07 million to expand our proprietary cell platforms. This includes advancing our off-the-shelf Gamma Delta T (GDT) cell culture platforms, which is...

CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, CosmoFarm S.A. (“CosmoFarm”), delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million. CosmoFarm added more than 80 new pharmacies to its distribution network during the period, continuing the strong customer growth that has made it one of the leading pharmaceutical wholesalers in the greater Athens area. To support this accelerating growth, Cosmos Health is increasing capital expenditure at CosmoFarm, investing in new robotic automation and artificial intelligence systems to enhance procurement, inventory management, and...

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDAResubmission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the fiscal year ended March 31, 2026. “Since receipt of the U.S. Food and Drug Administration’s (FDA) Complete...

Continued Sales Momentum in National Pharmacy Chains Drives Increase in YOY Revenues and Raises Growth Outlook For 2026GlucoDown® is the first nutritional beverage enriched with our special form of soluble fiber which, clinical data indicates, can reduce your body’s metabolism of dietary sugars. In this way, GlucoDown®’s special soluble fiber helps to moderate increases in blood glucose levels, especially after meals.Bentonville, ARKANSAS, June 18, 2026 (GLOBE NEWSWIRE) — Glucose Health, Inc. (OTCID:GLUC), the maker of GlucoDown®, a scientifically formulated blood sugar support beverage, today announced continued growth and increasing momentum within the national pharmacy channel as demand from two of the largest U.S. pharmacy chains strengthened during the second quarter of 2026.  The Company recently...

Ethel Mora, CEO of Swell.Ethel Mora, CEO of Swell, the Mexican non-bank financial institution whose BBB- rating was reaffirmed by HR Ratings for a second consecutive year.MEXICO CITY, June 18, 2026.- Swell, a leading Mexican credit provider, has had its BBB- rating reaffirmed with a Stable Outlook by HR Ratings for a second consecutive year. HR Ratings announced the decision on June 17, 2026. Swell is a Mexican non-bank financial institution focused on financing small and medium-sized enterprises (SMEs). The agency also affirmed Swell’s HR3 short-term rating, citing improvements in capitalization, profitability, financial efficiency, and funding diversification, and a capitalization ratio of 37.9%, supported by earnings generation and operational efficiencies. It also cited a 3.4% return on assets (ROA), tied to a wider...

STABLE DEVELOPMENT IN UNCERTAIN TIMES Third QuarterNet sales amounted to SEK 1,441 million (1,375), an increase of SEK 66 million, 5 percent. Operating profit amounted to SEK 347 million (377), a decrease of SEK 30 million, 8 percent. Operating profit adjusted for capital gains from exploitation assets amounted to SEK 346 million (347), a decrease of SEK 1 million, 0 percent. Capital gains from exploitation assets were included with SEK 1 million (30). Cash flow from operating activities amounted to SEK -368 million (-460), an increase of SEK 92 million. Basic and diluted earnings per share amounted to SEK 3.43 (3.82), a decrease of 10 percent.First Nine MonthsNet sales amounted to SEK 4,663 million (4,348), an increase of SEK 315 million, 7 percent. Operating profit amounted to SEK 1,146 million (1,095), an increase of SEK 51 million,...

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028 BOSTON, June 17, 2026 (GLOBE NEWSWIRE) — Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the first quarter ended March 31, 2026 and highlighted progress across its clinical and preclinical portfolio. “During...